Skip to main content
Premium Trial:

Request an Annual Quote

TGen to Conduct Phase I Study of Prolexys Anti-Cancer Drug

Prolexys Pharmaceuticals yesterday announced the start of its first human trials of PRLX 93936, a potential anti-cancer compound.
 
Among the study centers performing the phase I studies of this erastin analog is TGen Clinical Research. At TGen and the other study sites, the safety, efficacy, and pharmocodynamic properties of PRLX 93936 will be evaluated in patients with advanced solid tumors.
 
"Rarely have we seen pre-clinical anti-tumor effects that match those produced by PRLX 93936," Daniel Von Hoff, the director of clinical research at TGen, and the principal investigator for the study at Scottsdale Healthcare, said in a prepared statement. "We're very hopeful that this compound will have a therapeutic effect in patients with tumors that are non-responsive to existing therapeutic agents."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.